GlobeNewswire

Klox Technologies announces positive top-line results from a pivotal study of Phovia(TM) for the management of Canine Deep Pyoderma

Dela

https://editorial.globenewswire.com/ResourceLibrary/ResourceLibrary/GetDynamicThumbnailContentContent/?resourceId=11bfa272-6e3e-4ced-ada8-cf95475c79c0&maxHeight=150&maxWidth=150

DUBLIN, Ireland, July 02, 2018 (GLOBE NEWSWIRE) -- Klox Technologies Limited, a subsidiary of Klox Technologies Inc. ('KTI') has announced they have completed a pivotal study of Phovia for the management of Canine Deep Pyoderma. The 80-patient study met all endpoints and demonstrated that Phovia significantly reduces time to clinical resolution while reducing the duration of antibiotic use. 

Phovia is a first-in-class, topical fluorescence biomodulating product, using proprietary technology, to engage inherent biological systems.

This prospective, randomized, controlled, blinded study compared the current standard of care (systemic antibiotic therapy) versus the standard of care plus Phovia twice weekly, until clinical resolution was achieved.

Phovia demonstrated efficacy for the primary endpoint, with the proportion of patients reaching clinical resolution at six (6) weeks being 26.5% for the control group and 84.6% for the Phovia treated group (p<0.001). The statistically significant differences between the two (2) groups were obtained as soon as week three (3). For the secondary endpoints, the Phovia treated group showed a statistically significant reduction of clinical scores, and an improvement in neutrophil engulfing bacteria scores. An exploratory endpoint demonstrated that the median time to clinical resolution for the control group was 12.7 weeks while the Phovia treated group was 4.0 weeks; a significant reduction in treatment times. No product related adverse events were recorded.

Prof. Andrea Spaterna from the University of Camerino, Italy, and principal investigator of the Phovia study, stated that, "Reducing the treatment time of deep pyodermas to this extent is tremendous news for veterinarians, patients and owners alike. A critical part of the results includes reducing the duration of systemic antibiotic use, as it is becoming abundantly clear in the international community that long-term antibiotic use has a high risk factor for the development of antibiotic resistant bacteria."

Investigators strongly believe that a product like Phovia is ready for the veterinary market, as veterinarians and pet owners are more reluctant to treat patients with long-term antibiotics. "I am finding most pet owners are really open to innovative therapies like Phovia, and having the patients come into the clinic for treatment allows for better monitoring of deep pyodermas", concluded Prof. Spaterna.

Klox is advancing discussions with potential partners to bring Phovia, and its pipeline products to market. Partnerships are expected to be announced later this year, and Phovia is anticipated to be commercially available in Europe during H1 2019.

About Phovia(TM)

Phovia is a first-in-class, topical fluorescence biomodulating product, using proprietary technology, to engage inherent biological systems. It is based on Klox's patented Fluorescence Biomodulation technology platform, which is a non-invasive, non-thermal technology targeted to improve the management of serious skin/soft tissue disorders for companion animals and horses. It is intended to create an environment that promotes accelerated healing of pyoderma lesions in dogs and promotes wound healing in dogs, cats and horses.

About Canine Deep Pyoderma                                                                                                                            

Canine deep pyoderma (CDP) is a difficult to treat skin disease in small animals1 characterized by dissemination of bacteria into the deep dermis and/or bacterial infection of the panniculus. The causative organism is Staphylococcus pseudintermedius(formerly S. intermedius) in the vast majority of cases. Bacteria in lesions of deep pyoderma are often located in the center of fibrotic or inflammatory foci, associated with chronic diseases and scarring. Recurrence of the disease is frequent, which requires long-term systemic antibiotic use, and an additional one to two (2) weeks of extended antibiotic use post clinical resolution to ensure complete microbiological remission2,3.

About Klox Technologies

Klox Technologies Inc. is a private biomedical technology innovator, advancing the development and commercialization of its flagship fluorescence generating technology for specific skin/soft tissue conditions and diseases. With franchises in wound care, dermatology, veterinary and oral health, Klox is well positioned to capitalize on significant market opportunities. For more information please visit www.kloxtechnologies.com

Contact

Klox Technologies Limited
Dr. Ricardo Garvao, Head of Animal Health
rgarvao@kloxtechnologies.com
+353 (0) 1 7006216

References:

  1. Lund EM, Armstrong PJ, Kirk CA et al. Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. Journal of the American Animal Hospital Association 1999; 214: 1336-41.
  2. Scott DW, Miller WH Jr, Griffin CE. Muller and Kirk's Small Animal Dermatology, 6th edn, ed. Philadelphia: W.B. Saunders, 2001; 453-7.
  3. Spaterna A. Dermatosi a carattere pustoloso e/o foruncoloso. In: Spaterna A. Dermatologia del cane, dal segno clinico alla diagnosi e terapia, Point Vet. Italie Ed., Milano, 2008; 139-170.



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Klox Technologies, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum